Breaking News Instant updates and real-time market news.

TXMD

TherapeuticsMD

$5.67

0.5 (9.67%)

08:21
04/12/18
04/12
08:21
04/12/18
08:21

TherapeuticsMD talks with FDA incrementally positive, says Jefferies

Jefferies analyst Matthew Andrews believes label negotiations with the FDA on TX-004 is incrementally positive for TherapeuticsMD. The company is one step closer to approval after a tough 2017, Andrews tells investors in a research note. Amid the potential for two FDA approvals in 2018, no near-term financing overhang and potential for stronger than expected TX-004 launch, shares of TherapeuticsMD are undervalued, the analyst contends. He keeps a Buy rating on the stock with a $15 price target.

  • 08

    May

  • 29

    May

  • 28

    Oct

TXMD TherapeuticsMD
$5.67

0.5 (9.67%)

01/16/18
JEFF
01/16/18
NO CHANGE
Target $15
JEFF
Buy
TherapeuticsMD undervalued at current share levels, says Jefferies
Following a dinner with management, Jefferies analyst Matthew Andrews calls shares of TherapeuticsMD undervalued. TX-004HR is a differentiated novel estrogen drug while TX-001HR is a potential new "gold standard" in vasomotor symptoms, Andrews tells investors in a research note partially titled "2018 to Bring Innovation Back to Women's Health." With new drug applications for both under FDA review, TherapeuticsMD is on track for two approvals in 2018, a "rare biopharma achievement," in the multi-billion vaginal atrophy and vasomotor symptoms markets, the analyst writes. He keeps a Buy rating on TherapeuticsMD with a $15 price target.
02/21/18
JEFF
02/21/18
NO CHANGE
Target $15
JEFF
Buy
TherapeuticsMD undervalued into 'transformative' 2018, says Jefferies
Jefferies analyst Matthew Andrews believes 2018 is set up to be a "transformative" year for TherapeuticsMD with two FDA approvals, which he notes is a rarity in small-cap biotech. Finalization of a $200M term loan prior to TX-004HR approval will remove any financing overhang and helps fund both drugs' launches, Andrews tells investors in a research note. He views the stock as undervalued and thinks TX-001HR can become the vasomotor symptoms "gold-standard drug" with $2B-plus in sales. The analyst keeps a Buy rating on TherapeuticsMD with a $15 price target.
02/21/18
CANT
02/21/18
NO CHANGE
Target $28
CANT
Overweight
TherapeuticsMD could have 'breakout year' in 2018, says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner reiterates an Overweight rating and $28 price target on shares of TherapeuticsMD following the company's Q4 results. The possibility of dual approvals could make for a "breakout year" in 2018, Tanner tells investors in a post-earnings research note. He believes TX-004 could become an important therapy with which to treat vulvar vaginal atrophy. Further, the "evolving regulatory landscape" for drug compounders should position TX-001 as an attractive alternative commercial product for compounding pharmacies, the analyst adds.
04/12/18
CANT
04/12/18
NO CHANGE
Target $28
CANT
Overweight
TherapeuticsMD talks with FDA 'tacit sign' of approval, says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner views TherapeuticsMD's disclosure of label negotiations with the FDA regarding TX-004 as a "tacit sign that the drug will be approved." The FDA action date is May 29 "so such an activity would be expected were the Agency prepared to issue a positive decision, in our experience," Tanner told investors yesterday in a research note. He cautions investors from viewing as probable an approval with a label that does not contain the estrogen class black box warning. However, given the drug's "tortuous development path," he believes any approval is a "clear positive." The analyst has an Overweight rating on TherapeuticsMD with a $28 price target.

TODAY'S FREE FLY STORIES

01:50
11/15/18
11/15
01:50
11/15/18
01:50
General news
Asian Market Wrap: »

Asian Market Wrap:…

APTX

Aptinyx

$24.75

-0.76 (-2.98%)

21:40
11/14/18
11/14
21:40
11/14/18
21:40
Initiation
Aptinyx initiated at Cantor Fitzgerald »

Aptinyx initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OVID

Ovid Therapeutics

$4.75

-0.42 (-8.12%)

21:39
11/14/18
11/14
21:39
11/14/18
21:39
Initiation
Ovid Therapeutics initiated at Cantor Fitzgerald »

Ovid Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

AXSM

Axsome Therapeutics

$2.82

-0.07 (-2.42%)

21:38
11/14/18
11/14
21:38
11/14/18
21:38
Initiation
Axsome Therapeutics initiated at Cantor Fitzgerald »

Axsome Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNLI

Denali Therapeutics

$17.53

0.24 (1.39%)

21:37
11/14/18
11/14
21:37
11/14/18
21:37
Initiation
Denali Therapeutics initiated at Cantor Fitzgerald »

Denali Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTIC

Otonomy

$2.34

-0.07 (-2.90%)

21:35
11/14/18
11/14
21:35
11/14/18
21:35
Initiation
Otonomy initiated at Cantor Fitzgerald »

Otonomy initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

AAPL

Apple

$186.81

-5.42 (-2.82%)

20:46
11/14/18
11/14
20:46
11/14/18
20:46
Hot Stocks
Apple supplier AMS AG discontinues FY18 targets »

Ams updates its fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

WEI

Weidai

$0.00

(0.00%)

20:33
11/14/18
11/14
20:33
11/14/18
20:33
Syndicate
Weidai 4.5M share IPO priced at $10.00 »

The deal was priced at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

CPB

Campbell Soup

$39.16

-0.1 (-0.25%)

20:31
11/14/18
11/14
20:31
11/14/18
20:31
Hot Stocks
Campbell Soup responds to ISS regarding board elections »

Campbell Soup issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

CRM

Salesforce

$129.25

-2.93 (-2.22%)

20:25
11/14/18
11/14
20:25
11/14/18
20:25
Periodicals
Breaking Periodicals news story on Salesforce »

Salesforce to accommodate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 06

    Dec

  • 11

    Dec

  • 03

    Mar

WMT

Walmart

$101.58

-1.37 (-1.33%)

, JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

20:25
11/14/18
11/14
20:25
11/14/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

WMT

Walmart

$101.58

-1.37 (-1.33%)

JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

BERY

Berry Global

$45.91

-0.49 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

BHVN

Biohaven Pharmaceutical

$33.70

-3.18 (-8.62%)

19:53
11/14/18
11/14
19:53
11/14/18
19:53
Recommendations
Biohaven Pharmaceutical analyst commentary at Piper Jaffray »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 27

    Nov

LOXO

Loxo Oncology

$143.69

-15.62 (-9.80%)

19:51
11/14/18
11/14
19:51
11/14/18
19:51
Initiation
Loxo Oncology initiated at Raymond James »

Loxo Oncology initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

  • 26

    Nov

  • 27

    Nov

OCUL

Ocular Therapeutix

$5.06

-0.25 (-4.71%)

19:50
11/14/18
11/14
19:50
11/14/18
19:50
Initiation
Ocular Therapeutix initiated at Raymond James »

Ocular Therapeutix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Dec

VYGR

Voyager Therapeutics

$11.25

-0.54 (-4.58%)

19:49
11/14/18
11/14
19:49
11/14/18
19:49
Upgrade
Voyager Therapeutics rating change at Raymond James »

Voyager Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

GLPG

Galapagos NV

$103.79

1.03 (1.00%)

19:48
11/14/18
11/14
19:48
11/14/18
19:48
Initiation
Galapagos NV initiated at Raymond James »

Galapagos NV initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COPY

CopyTele

$0.00

(0.00%)

19:47
11/14/18
11/14
19:47
11/14/18
19:47
Upgrade
CopyTele rating change at BMO Capital »

CopyTele upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICI

VICI Properties

$21.43

-0.04 (-0.19%)

19:40
11/14/18
11/14
19:40
11/14/18
19:40
Syndicate
VICI Properties 30M share Secondary priced at $21.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

WHD

Cactus

$32.37

-0.7 (-2.12%)

19:37
11/14/18
11/14
19:37
11/14/18
19:37
Hot Stocks
Cactus names Stephen Tadlock new CFO »

Cactus announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVLT

Revolution Lighting

$1.42

(0.00%)

19:32
11/14/18
11/14
19:32
11/14/18
19:32
Hot Stocks
Revolution Lighting receives revised $1.50 per share proposal from RVL LLC »

Revolution Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$8.34

-0.265 (-3.08%)

19:20
11/14/18
11/14
19:20
11/14/18
19:20
Periodicals
General Electric withdraws from Nigeria rail concession, Reuters says »

GE has withdrawn from a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCSF

Bain Capital Specialty Finance

$0.00

(0.00%)

19:11
11/14/18
11/14
19:11
11/14/18
19:11
Syndicate
Bain Capital Specialty Finance 7.5M share IPO price $20.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

TSLA

Tesla

$344.07

5.36 (1.58%)

19:07
11/14/18
11/14
19:07
11/14/18
19:07
Periodicals
Tesla Model 3 owners experience issues in cold weather, Electrek says »

Tesla Model 3 will face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 19

    Nov

  • 13

    Dec

NGHC

National General

$24.75

-3.05 (-10.97%)

19:05
11/14/18
11/14
19:05
11/14/18
19:05
Syndicate
National General 5M share Secondary priced at $24.00 »

JPMorgan, Goldman Sachs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 28

    Nov

  • 03

    Dec

  • 04

    Dec

  • 15

    Nov

WMT

Walmart

$101.58

-1.37 (-1.33%)

19:01
11/14/18
11/14
19:01
11/14/18
19:01
Periodicals
Walmart's Cornershop to expand into Canada next year, Reuters says »

Cornershop, a Latin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.